Recruiting
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
NCT07789184· Phase 3· Hua Huang, MD, PhD· Source
Contact: liang zong
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Jun Zhao
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Hong WU, Master
Recruiting
Mindfulness Intervention for Emotional Distress (MIED) in Patients With GERD
NCT07667894· Xinghua Liu· Source
Contact: Caiwen Yan, MBBS
Not yet recruiting
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
NCT07242599· Phase 3· Beijing Tiantan Hospital· Source
Contact: Bingxia Li
Recruiting
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xianping Zhao, Bachelor
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xianping Zhao, Bachelor
Not yet recruiting
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
NCT07087041· Beijing Friendship Hospital· Source
Contact: Bingqiong Wang, Dr
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Hong Wu
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
NCT07069842· Changzhi People's Hospital Affiliated to Changzhi Medical College· Source
Contact: Jun Zhao
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Na Si
Recruiting
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
NCT06434597· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source
Contact: Jun Zhao
Recruiting
Goal-directed Enteral Nutritional Perioperative Management
NCT06510543· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Changhong Lian, M.D.
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Jun Zhao, Doctor
Not yet recruiting
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127· Phase 3· Akeso· Source
Contact: Zhifang Yao, M.D.
Active, not recruiting
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
NCT05461339· Phase 3· BioDlink Biopharm Co., Ltd.· Source
Active, not recruiting
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147· Phase 3· Jazz Pharmaceuticals· Source
Active, not recruiting
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
NCT04854668· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source